| dc.contributor.author | Hui, R | |
| dc.contributor.author | Pearson, A | |
| dc.contributor.author | Cortes Castan, J | |
| dc.contributor.author | Campbell, C | |
| dc.contributor.author | Poirot, C | |
| dc.contributor.author | Azim, HA | |
| dc.contributor.author | Fumagalli, D | |
| dc.contributor.author | Lambertini, M | |
| dc.contributor.author | Daly, F | |
| dc.contributor.author | Arahmani, A | |
| dc.contributor.author | Perez-Garcia, J | |
| dc.contributor.author | Aftimos, PG | |
| dc.contributor.author | Bedard, P | |
| dc.contributor.author | Xuereb, L | |
| dc.contributor.author | Loibl, S | |
| dc.contributor.author | Loi, S | |
| dc.contributor.author | Pierrat, M-J | |
| dc.contributor.author | Turner, NC | |
| dc.contributor.author | André, F | |
| dc.contributor.author | Curigliano, G | |
| dc.date.accessioned | 2019-10-21T10:33:17Z | |
| dc.date.issued | 2019-12-05 | |
| dc.identifier.citation | Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 29 Suppl 8 pp. viii93 - ? | |
| dc.identifier.issn | 0923-7534 | |
| dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3386 | |
| dc.identifier.eissn | 1569-8041 | |
| dc.identifier.doi | 10.1093/annonc/mdy272.281 | |
| dc.format | Print | |
| dc.format.extent | viii93 - ? | |
| dc.language | eng | |
| dc.language.iso | eng | |
| dc.publisher | Elsevier BV | |
| dc.rights.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
| dc.title | Lucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial. | |
| dc.type | Journal Article | |
| dcterms.dateAccepted | 2019-10-09 | |
| rioxxterms.versionofrecord | 10.1093/annonc/mdy272.281 | |
| rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
| rioxxterms.licenseref.startdate | 2018-10 | |
| rioxxterms.type | Journal Article/Review | |
| dc.relation.isPartOf | Annals of oncology : official journal of the European Society for Medical Oncology | |
| pubs.notes | Not known | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Molecular Oncology | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Molecular Oncology | |
| pubs.publication-status | Published | |
| pubs.volume | 29 Suppl 8 | |
| pubs.embargo.terms | Not known | |
| icr.researchteam | Molecular Oncology | |
| dc.contributor.icrauthor | Pearson, Alex | |
| dc.contributor.icrauthor | Turner, Nicholas | |
